



PB 91 of 2025

National Health (Originator Brand) Amendment Determination (No. 5) 2025

I, Rebecca Richardson, Assistant Secretary, PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following Determination.

Dated 28 July 2025

REBECCA RICHARDSON

Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1
Schedule 1—Amendments	2
<i>National Health (Originator Brand) Determination 2015 (PB 100 of 2015)</i>	2

1 Name

This instrument is the *National Health (Originator Brand) Amendment Determination (No. 5) 2025*.

This instrument may also be cited as PB 91 of 2025.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	1 August 2025	

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99ADB(6B) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Originator Brand) Determination 2015 (PB 100 of 2015)

1 Schedule 1, (after table item 54)

Repeal:

55	Cyproterone	Androcur Androcur-100		
55A	Dabigatran etexilate	Pradaxa		
55B	Dapsone	Link Medical Products Pty Ltd		
55C	Darunavir	Prezista		
55D	Dasatinib	Sprycel		
55E	Deferasirox	Jadenu		

Substitute:

55	Cyproterone	Androcur Androcur-100		
55A	Dabigatran etexilate	Pradaxa		
55B	Dapsone	Link Medical Products Pty Ltd		
55C	Darunavir	Prezista		
55D	Dasatinib	Sprycel		
55E	Deferasirox	Jadenu		

55F	Denosumab	Prolia Xgeva		
-----	-----------	-----------------	--	--

2 Schedule 1, (after table item 70)

Repeal:

71	Duloxetine	Cymbalta		
71A	Dutasteride	Avodart		
71B	Dutasteride with tamsulosin	Duodart 500ug/400ug		

Substitute:

71	Drospirenone with ethinylestradiol	Yasmin Yaz		
71A	Duloxetine	Cymbalta		
71B	Dutasteride	Avodart		
71C	Dutasteride with tamsulosin	Duodart 500ug/400ug		

3 Schedule 1, (after table item 238)

Insert:

238A	Ustekinumab	Stelara		
------	-------------	---------	--	--